The Florida Department of Children and Families (DCF), Substance Abuse and Mental Health program, is soliciting proposals under DCF RFP 2627 020, Emergency Opioid Antagonist Products and Resources (MFMP opportunity RFP-16548) for its statewide Overdose Prevention Program.
Current deadline: Current MFMP-derived tracking shows November 10, 2026 after DCF posted Addendum No. 03 on September 10, 2026 with a timeline update. Atlas has not independently recovered the current Addendum No. 03 clock time and time zone from the controlling MFMP package, so no exact time is being invented. The original Florida Administrative Register notice used an earlier September response-opening date and expressly directs prospective vendors to the Vendor Information Portal for changes and additional notices.
Scope: The procurement seeks a provider able to supply multiple formulations of emergency opioid antagonist products and related resources for statewide overdose prevention. Current solicitation mirrors describe delivery to approximately 1,500 DCF-authorized enrolled distributors, an ordering and reporting portal, account-management services, tracking, and monthly reporting. They also reflect product requirements including U.S. manufacture/assembly and remaining shelf-life requirements. Prospective vendors must rely on the live MFMP solicitation and all current addenda for controlling specifications.
Funding: Atlas did not verify a published contract ceiling or guaranteed procurement amount. Third-party budget estimates are not treated as controlling funding.
Eligibility and vendor qualifications: This is a vendor procurement rather than an applicant grant. A respondent must be able to furnish the required emergency opioid antagonist products and associated statewide distribution, portal, account-management, tracking, reporting, and compliance services from contract start. Pharmaceutical manufacturers, authorized medical/pharmaceutical distributors, and other organizations able to satisfy the full solicitation requirements are the practical respondent class. The live MFMP package controls all mandatory qualifications and proposal forms.
Submission and amendments: Vendors should submit through the method specified in the current MyFloridaMarketPlace/Vendor Information Portal solicitation and review every posted amendment. Addendum No. 03 is the latest timeline update identified by Atlas in current tracking.
Contact: MFMP-derived solicitation records identify Sally Johns at sally.johns@myflfamilies.com as a procurement contact. Vendors should confirm the current contact block in MFMP before submitting procurement communications.
Atlas assessment: Atlas Opportunity Score 74/100 because the procurement is a legitimate statewide behavioral-health and overdose-prevention acquisition, but it is narrowly oriented to pharmaceutical products and large-scale distribution capability. N9+ Fit Score 2/100; Atlas found no material N9+ role in the required scope. QC Healthcare/Dr. Miltie fit is approximately 5/100. Dr. Miltie direct-prime eligibility is not established and should not be advanced without proof of authorized opioid-antagonist supply capability, required formulations, statewide logistics, and ordering/reporting infrastructure. No applicant outreach is recommended.